Why the study?
Does spironolactone reduce arrhythmias, myocardial fibrosis markers, and endothelial dysfunction in patients with CAD but without heart failure?
Does spironolactone reduce arrhythmias, myocardial fibrosis markers, and endothelial dysfunction in patients with CAD but without heart failure?
Spironolactone significantly reduces ventricular extrasystoles, QT interval, and markers of myocardial fibrosis in patients with CAD without heart failure, suggesting a potential antiarrhythmic benefit.
No takes yet. Share an insight, caveat, or question.
Supports spironolactone for arrhythmic risk reduction in CAD without HF; extends MRA benefits beyond systolic dysfunction.
Shah et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: